By / January 8, 2020

Big plans for the Big Pharma cannabis industry

Cannabis is revolutionizing sectors such as health, economy, trade, finance, and environmental care. The Big Pharma cannabis industry is another one of them.

The chemical-pharmaceutical industry uses large multinational laboratories concentrated on the cannabis and patent market.

Big Pharma cannabis companies are taking steps to go beyond monitoring and observing the phenomenon and are increasingly announcing investment plans to participate in this juicy business. is a mobile application that is exclusively dedicated to hemp news as well as the very latest news about the general hemp and cannabis industry. The App covers topics like the latest changes in cannabis legalization, health benefits of hemp, and more.

The Big Pharma cannabis concept

The Big Pharma cannabis concept encompasses the largest and most influential pharmaceutical companies, which play a leading role in this industry worldwide.

Big Pharma has been cautious about entering the cannabis industry, especially given the regulatory hurdles and difficulties that remain in many countries, which they see as risks for investment in this market.

Cannabis has a long history, as its use for medical purposes goes back at least 6,000 years. However, in some circles, there is still debate about its curative and medical uses, despite the abundant evidence and research protocols that have demonstrated its benefits.

Cannabis as disease treatment

Studies on the therapeutic properties of CBD confirm its usefulness in combating diseases such as epilepsy, schizophrenia, multiple sclerosis, migraines, arthritis and cancer side effects.

In addition, the U.S. Department of Health and Social Services (FEED) has obtained a patent for the use of CBD in the treatment of neurodegenerative and inflammatory diseases, including Alzheimer’s.

The U.K. based magazine Clinical Pharmacology determined that the CBD oil and seeds of the plant are efficient in the treatment of convulsions, tumors, inflammations, cancer, and depression.

Woman holding bottle and beaker representing the Big Pharma cannabis industry
Big Pharma is attracted to the medical properties of cannabis, but they are also aware of the risks in the industry. (Source)

In light of this evidence, 33 U.S. states have legalized cannabis for medical use. All this research is triggering the Big Pharma cannabis incursion, which will contribute to revolutionizing other peripheral industries.

Big Pharma cannabis sales

Further legalization and regulation of cannabis will enable Big Pharma to achieve annual sales of approximately $6 billion by 2019 of medical cannabis in all forms, for an estimated market of 24 million patients.

Seven of the top ten cannabis patent holders in Canada and the U.S. are large multinational pharmaceutical companies. Many of these pharmaceutical giants have formed partnerships with cannabis companies such as Novartis and Tilray.

Products with supporting scientific evidence and protocols are today the spearhead for the Big Pharma cannabis mass entry.


(Featured image by LeilaSchmidt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Zócalo, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.